ReviewPharmaceutics2022
A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Buccal Insulin Delivery Systems: Formulation Approaches, Stability Constraints, and Translational Prospects.Pharmaceutics · 2026Review
- Improved Messenger RNA Stability and Biocompatibility Through Self-Gelatinizable Nucleic Acids.Biotechnology and bioengineering · 2026Article
- Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus.Reviews in endocrine & metabolic disorders · 2025Review
- Insulin-Enhanced Biological Visual Rehabilitation in Neuroretinal Degeneration Patients Treated with Mesenchymal Cell-Derived Secretome.Pharmaceutics · 2025Article
- In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Prospects for the convergence of polyphenols with pharmaceutical drugs in type 2 diabetes: Challenges, risks, and strategies.Pharmacological reviews · 2025Review
- Effectiveness, safety, and preference of transdermal insulin compared to subcutaneous insulin in the treatment of diabetes patients: a systematic review of clinical trials.Diabetology & metabolic syndrome · 2024Review
- Advancements in Insulin Pumps: A Comprehensive Exploration of Insulin Pump Systems, Technologies, and Future Directions.Pharmaceutics · 2024Review
- What Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art.Biomedicines · 2024Review
- [Evolution of insulin therapy: past, present, future].Problemy endokrinologii · 2024Review
- Article
- Recent Advancement of Medical Patch for Transdermal Drug Delivery.Medicina (Kaunas, Lithuania) · 2023Review
- Current Development of Chemical Penetration Enhancers for Transdermal Insulin Delivery.Biomedicines · 2023Review
- Harnessing gut cells for functional insulin production: Strategies and challenges.Biotechnology notes (Amsterdam, Netherlands) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
The year 2021 marks the 100th anniversary of the momentous discovery of insulin. Through years of research and discovery, insulin has evolved from poorly defined crude extracts of animal pancreas to recombinant human insulin and analogues that can be prescribed and administered with high accuracy and efficacy. However, there are still many challenges ahead in clinical settings, particularly with respect to maintaining optimal glycemic control whilst minimizing the treatment-related side effects of hypoglycemia and weight gain. In this review, the chronology of the development of rapid-acting, short-acting, intermediate-acting, and long-acting insulin analogues, as well as mixtures and concentrated formulations that offer the potential to meet this challenge, are summarized. In addition, we also summarize the latest advancements in insulin delivery methods, along with advancement to clinical trials. This review provides insights on the development of insulin treatment for diabetes mellitus that may be useful for clinicians in meeting the needs of their individual patients. However, it is important to note that as of now, none of the new technologies mentioned have superseded the existing method of subcutaneous administration of insulin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.